AIDS-related Kaposi's sarcoma can occur during peginterferon-α and ribavirin therapy for chronic hepatitis C infection.

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) Pub Date : 2012-01-01 Epub Date: 2011-09-20 DOI:10.1177/1545109711420875

Victoire de Lastours, Juliette Pavie, Constance Delaugerre, Jean-Michel Molina

{"title":"AIDS-related Kaposi's sarcoma can occur during peginterferon-α and ribavirin therapy for chronic hepatitis C infection.","authors":"Victoire de Lastours, Juliette Pavie, Constance Delaugerre, Jean-Michel Molina","doi":"10.1177/1545109711420875","DOIUrl":null,"url":null,"abstract":"Introduction: Before the arrival of highly active antiretroviral therapy (HAART), interferon α has been used successfully to treat AIDS-related Kaposi's sarcoma (KS). Peginterferon-α (pegIFN-α) may still be used successfully in refractory KS.Case: Peginterferon-α and ribavirin (RBV) were initiated to treat hepatitis C virus (HCV) infection in an HIV-infected patient with high CD4 counts having discontinued antiretroviral therapy (ART). He developed disseminated KS 6 months after HCV treatment began. Beginning of ART, discontinuation of pegIFN/RBV, and 2 cycles of doxorubicine were necessary to treat KS.Discussion: Despite its activity on KS, thanks to its antiviral and antiangiogenic properties, PegIFN was unable to prevent the occurrence of severe KS. The absence of ART, despite high CD4 counts, and interferon-induced lymphopenia probably triggered the occurrence of KS in this patient.","PeriodicalId":86092,"journal":{"name":"Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)","volume":"11 1","pages":"9-11"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1545109711420875","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1545109711420875","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/9/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Before the arrival of highly active antiretroviral therapy (HAART), interferon α has been used successfully to treat AIDS-related Kaposi's sarcoma (KS). Peginterferon-α (pegIFN-α) may still be used successfully in refractory KS.

Case: Peginterferon-α and ribavirin (RBV) were initiated to treat hepatitis C virus (HCV) infection in an HIV-infected patient with high CD4 counts having discontinued antiretroviral therapy (ART). He developed disseminated KS 6 months after HCV treatment began. Beginning of ART, discontinuation of pegIFN/RBV, and 2 cycles of doxorubicine were necessary to treat KS.

Discussion: Despite its activity on KS, thanks to its antiviral and antiangiogenic properties, PegIFN was unable to prevent the occurrence of severe KS. The absence of ART, despite high CD4 counts, and interferon-induced lymphopenia probably triggered the occurrence of KS in this patient.

查看原文本刊更多论文

与艾滋病相关的卡波西肉瘤可在聚乙二醇干扰素-α和利巴韦林治疗慢性丙型肝炎感染期间发生。

导语:在高效抗逆转录病毒疗法(HAART)出现之前，干扰素α已被成功用于治疗艾滋病相关的卡波西肉瘤(KS)。聚乙二醇干扰素-α (pegIFN-α)仍可成功用于难治性KS。病例:聚乙二醇干扰素-α和利巴韦林(RBV)开始治疗丙型肝炎病毒(HCV)感染的hiv感染患者的CD4高计数已停止抗逆转录病毒治疗(ART)。他在HCV治疗开始6个月后出现播散性KS。开始抗逆转录病毒治疗，停止pegIFN/RBV, 2个周期的阿霉素是治疗KS的必要条件。讨论:尽管PegIFN对KS有作用，但由于其抗病毒和抗血管生成的特性，PegIFN不能预防严重KS的发生。尽管CD4计数很高，但ART的缺乏和干扰素诱导的淋巴细胞减少可能引发了该患者KS的发生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)

自引率

0.00%

发文量